Valuable Service Providers or Fox in the Henhouse?
Pharmacy Benefit Managers, their role in drug pricing and the growing debate around transparency and regulation
Pharmacy Benefit Managers (PBMs) are intermediary service providers between health insurers, drug manufacturers and pharmacies. They emerged in the 1960s to help manage prescription drug programs, initially performing simple tasks like claims processing. However, as healthcare evolved, so did the role of PBMs. Today, they negotiate drug prices, create formularies (the list of covered drugs) and determine reimbursement levels for pharmacies. They also use tools like prior authorizations and step therapy to manage which medications patients can access—aiming to keep costs in check for insurers and employers. PBMs have become a significant part of the healthcare ecosystem, with major players like CVS Caremark managing benefits for millions of Americans.
PBMs have been credited with helping reduce costs for health plans through rebates and price negotiations, but they have also come under fire for contributing to rising drug prices. Proponents argue that PBMs help reduce drug spending through cost-containment strategies, while critics highlight the lack of transparency, potential conflicts of interest and their role in inflating drug costs for patients. As PBMs have gained power in the drug supply chain, their influence has led to increased scrutiny by regulators and patient advocates alike.
While PBM’s have been active for decades, legislative changes in the past 20 years accelerated their growth. The introduction of Medicare Part D in 2006 significantly increased the demand for PBMs, as they were contracted to manage prescription benefits for millions of Medicare enrollees. The passage of the Affordable Care Act in 2010 increased insurance coverage and expanded prescription drug utilization. These changes drove consolidation in the PBM industry, leading to mergers and acquisitions that created a monopolistic marketplace. By 2021, the three largest PBMs—CVS Caremark, Express Scripts and OptumRx—controlled more than 70% of the U.S. prescription drug market.
Pricing power is clearly driving profits: In 2022, CVS Health’s PBM arm reported a revenue of $153 billion—representing a significant portion of the company’s overall business. Similarly, the other two giants, Express Scripts (which is part of Cigna) and OptumRx (part of UnitedHealth Group), have shown steady revenue growth in both topline and total share of overall business. The profitability stems largely from the rebates, spread pricing and administrative fees which have been identified as a primary agent for the lack of transparency. Margins in the PBM business can vary, but some estimates suggest that when rebates are included PBMs may collect up to 40% of the total drug spend in certain cases, particularly when dealing with high-cost specialty drugs.
Pros
- Negotiating Lower Prices: PBMs negotiate rebates and discounts with pharmaceutical companies, which can reduce overall drug costs for insurers and employers.
- Formulary Management: By managing drug formularies, PBMs encourage the use of cost-effective generic drugs and lower-priced alternatives, saving money for both patients and health plans.
- Cost Containment Tools: PBMs use tools like prior authorization and step therapy to manage drug utilization, ensuring that more expensive treatments are used only when absolutely necessary.
Cons
- Lack of Transparency: Critics argue that PBMs do not disclose the full extent of the rebates they receive from drug manufacturers, leaving insurers and patients uncertain about actual costs.
- Rebate-Driven Price Inflation: PBMs’ emphasis on securing higher rebates can lead to inflated list prices, as manufacturers raise prices to compensate for the discounts provided to PBMs.
- Patient Access Issues: The cost-containment tools employed by PBMs, like prior authorization, can sometimes delay or deny patient access to necessary medications, leading to frustration and potential health risks.
Why Should We Care?
The role of PBMs is significant due to their direct impact on healthcare costs. As they mediate drug pricing, formularies and reimbursement models, they have the power to influence what patients pay for medications. PBMs’ ability to prioritize rebates over patient care means there is potential for inefficiency and profit-driven motives that do not align with optimal patient outcomes. To over-simplify, imagine doubling the price of a grocery item and then declaring a 30% discount while pocketing the rest.
A well-known example is the case of insulin: Between 2012 and 2016, the price of insulin nearly tripled, despite the medication being available for decades. PBMs were arguably responsible for much of the increase because of their rebate-driven model. PBMs negotiated higher rebates with insulin manufacturers, but passed on the new rates to consumers. As a result, patients saw their out-of-pocket costs skyrocket, while PBMs and insurance companies benefited financially from the rebates.
PBMs also participate in spread pricing, where they charge health plans significantly more for a drug than what they reimburse to the pharmacy, keeping the difference. A 2018 Ohio state audit revealed that PBMs had collected $223 million in hidden fees from the state’s Medicaid program due to spread pricing. This practice has led to accusations that PBMs inflate drug prices, contributing to higher healthcare costs.
In response to growing scrutiny, there is increased policy focus on regulating PBMs. The Federal Trade Commission has launched investigations into PBM practices—particularly regarding their role in inflating drug prices and limiting competition. Policies such as the Drug Price Negotiation Act and recent Medicare reforms have focused on increasing the accountability of PBMs. Proposed changes include banning certain pricing tactics like “spread pricing” and mandating that savings be passed directly to patients. Regulatory bodies and lawmakers are also discussing new transparency measures to address the opaqueness in rebate structures and ensure fair competition in the pharmaceutical supply chain.
Pharmacy Benefit Managers play a significant role in shaping the pharmaceutical landscape, controlling drug pricing and influencing access to medication. While they offer cost-management benefits, they also face increasing scrutiny for their lack of transparency and potential contribution to rising drug costs. As ongoing regulatory efforts seek to address these concerns, the future of PBMs remains a critical subject for both policymakers and healthcare stakeholders. Stay tuned for more insights as we continue to explore this evolving industry.
Sources:
